Search reports, ask a question, or jump to a page.
The problem
Intervention: Provision of nirsevimab, a respiratory syncytial virus infant monoclonal antibody, to newborns during infancy
Who it was tested with: Post-partum women (n=476) in Southern Italian teaching and public hospitals, March-April 2025.
Experience from people who deliver programmes: stories, case studies and lessons learned. Valuable for understanding how and why, and for spotting what to test next, but not a measure of effect.
"The survey was conducted between March and April 2025 in teaching and public hospitals randomly selected in Southern Italy. The data were collected using a structured questionnaire through a face-to-face interview for those women in the maternity wards and by telephone for those who were at home." This is a self-report survey of parental acceptance and immunization uptake without clinical outcome measures or a control group.
Cross-sectional design with no comparison group or longitudinal follow-up; self-reported acceptance and immunization status; limited to Southern Italy and may not generalize; no data on actual health outcomes or effectiveness of the antibody in preventing RSV disease.
Across countries and designs
8 studies · 17 countries
Classified by the Hub's AI
Not yet reviewed by a person. Model output is not AICS's view until reviewed.
claude-haiku-4-5-20251001 · synth-v1
